Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levodopa. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 7/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | USP2 | O75604 | 1/20 | 0.69 |
| ▸ | EGFR | P00533 | 1/20 | 0.69 |
| ▸ | LCK | P06239 | 1/20 | 0.69 |
| ▸ | FYN | P06241 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.69 |
| ▸ | HTR2A | P28223 | 1/20 | 0.69 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.69 |
| ▸ | RECQL | P46063 | 1/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.48 |
| ▸ | KDM6B | O15054 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levodopa SCHEMBL20637810 | 1.00 | SLC7A5 (0.69) | SLC7A5PTGS1ALOX15KDM4EUSP2 | |
| Levodopa SCHEMBL170258 | 1.00 | SLC7A5 (0.69) | SLC7A5PTGS1ALOX15KDM4EUSP2 | |
| Levodopa SCHEMBL27642065 | 0.89 | SLC7A5 (0.87) | SLC7A5PTGS1ALOX15KDM4EUSP2 | |
| Levodopa SCHEMBL896629 | 0.89 | SLC7A5 (0.87) | SLC7A5PTGS1ALOX15KDM4EUSP2 | |
| Dl-Phenylalanine SCHEMBL28481409 | 0.88 | SLC7A5 (0.73) | SLC7A5PTGS1ALOX15KDM4EHIF1A | |
| Dl-Phenylalanine SCHEMBL28169117 | 0.88 | SLC7A5 (0.73) | SLC7A5PTGS1ALOX15KDM4EHIF1A | |
| Tyrosine SCHEMBL4908261 | 0.87 | SLC7A5 (0.69) | SLC7A5PTGS1ALOX15KDM4EUSP2 | |
| SCHEMBL29913698 | 0.86 | KDM6B (0.62) | SLC7A5PTGS1ALOX15KDM4EUSP2 | |
| Levodopa SCHEMBL8579019 | 0.85 | SLC7A5 (0.79) | SLC7A5PTGS1ALOX15KDM4EUSP2 | |
| Levodopa SCHEMBL8579024 | 0.85 | SLC7A5 (0.79) | SLC7A5PTGS1ALOX15KDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111850526-A | In-situ repair method for surface metal coating | 中国电子科技集团公司第五十四研究所 | 2020-10-30 | — | — | CN | claimed |
| CN-107522827-B | Photocuring 3D printing photosensitive resin and preparation method and application thereof | 杨军 | 2020-08-21 | — | — | CN | claimed |
| US-20220229077-A1 | DIAGNOSIS, PROGNOSIS AND TREATMENT FOR SCHIZOPHRENIA AND SCHIZOAFFECTIVE PSYCHOSIS | PRECISION MEDICINE HOLDINGS PTY LTD (AU) | 2022-07-21 | — | — | US | disclosed |
| CN-113026123-B | Rotating device and electrostatic spinning device | 哈尔滨工业大学（深圳） | 2022-04-01 | — | — | CN | disclosed |
| CN-113712102-A | Health tea and preparation process thereof | 丛志弘 | 2021-11-30 | — | — | CN | disclosed |
| CN-110023752-B | Diagnosis, prognosis and treatment of schizophrenia and schizoaffective disorders | 精密医药控股私人有限公司 | 2021-06-29 | — | — | CN | disclosed |
| CN-113041846-A | Composite membrane yarn and preparation method thereof | 哈尔滨工业大学（深圳） | 2021-06-29 | — | — | CN | disclosed |
| CN-113026123-A | Rotating device and electrostatic spinning device | 哈尔滨工业大学（深圳） | 2021-06-25 | — | — | CN | disclosed |
| EP-3823626-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTISM | Yamo Pharmaceuticals LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3823593-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTISM | Yamo Pharmaceuticals LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-20210128508-A1 | Compositions And Methods For Treating Autism | YAMO PHARMACEUTICALS LLC (US) | 2021-05-06 | — | — | US | disclosed |
| US-20200049722-A1 | DIAGNOSIS, PROGNOSIS AND TREATMENT FOR SCHIZOPHRENIA AND SCHIZOAFFECTIVE PSYCHOSIS | PRECISION MEDICINE HOLDINGS PTY LTD (AU) | 2020-02-13 | — | — | US | disclosed |
| WO-2020018292-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTISM | YAMO PHARMACEUTICALS LLC (US) | 2020-01-23 | — | — | WO | disclosed |
| WO-2020018291-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTISM | YAMO PHARMACEUTICALS LLC (US) | 2020-01-23 | — | — | WO | disclosed |
| US-20190015365-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTISM | YAMO PHARMACEUTICALS LLC (US) | 2019-01-17 | — | — | US | disclosed |
| US-20190015364-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTISM | YAMO PHARMACEUTICALS LLC (US) | 2019-01-17 | — | — | US | disclosed |
| CN-104582729-B | Neoblast composition and its production and use | 斯丹姆涅恩有限公司 | 2017-07-18 | — | — | CN | disclosed |
| CN-104582729-A | Novel cell compositions and methods and uses thereof | STEMNION INC | 2015-04-29 | — | — | CN | disclosed |
| CN-101481745-B | Method for damaging oxidase in cane juice | UNIV GUANGXI TECHNOLOGY | 2011-08-31 | — | — | CN | disclosed |
| CN-101481745-A | Method for damaging oxidase in cane juice | GUANGXI UNIVERSITY OF TECHNOLO (CN) | 2009-07-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190015365-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTISM | MECP2, AADAT, CHAT | SLC7A5 2139/4885PTGS1 3565/4885ALOX15 2760/4885 |
| US-20190015364-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTISM | MECP2, AADAT, CHAT | SLC7A5 2139/4885PTGS1 3565/4885ALOX15 2760/4885 |
| US-20210128508-A1 | Compositions And Methods For Treating Autism | MECP2, AADAT, CHAT | SLC7A5 2139/4885PTGS1 3565/4885ALOX15 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.